Vaccine against norovirus

Tan, Ming; Jiang, Xi

doi:10.4161/hv.28626

Cited by 28 publications

(26 citation statements)

References 95 publications

(117 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…120 The P particle is an octahedral nanoparticle that is being considered as candidate for norovirus vaccine, as well as a delivery system for other antigens, such as rotavirus, influenza and hepatitis E. 17 This candidate induced both coli expression systems, in contrast to VLPs that use eukaryotic expression systems, may be an advantage for massive antigen production. 112 Vaccine candidates in preclinical development being only distributed in India.…”

Section: P Particle-based Vaccines: Researchers From the Cincinnati Cmentioning

confidence: 99%

See 1 more Smart Citation

Vaccines for viral and bacterial pathogens causing acute gastroenteritis: Part I: Overview, vaccines for enteric viruses andVibrio cholerae

O’Ryan

Vidal

Canto

et al. 2015

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

Efforts to develop vaccines for prevention of acute diarrhea have been going on for more than 40 y with partial success. The myriad of pathogens, more than 20, that have been identified as a cause of acute diarrhea throughout the years pose a significant challenge for selecting and further developing the most relevant vaccine candidates. Based on pathogen distribution as identified in epidemiological studies performed mostly in low-resource countries, rotavirus, Cryptosporidium, Shigella, diarrheogenic E. coli and V. cholerae are predominant, and thus the main targets for vaccine development and implementation. Vaccination against norovirus is most relevant in middle/high-income countries and possibly in resource-deprived countries, pending a more precise characterization of disease impact. Only a few licensed vaccines are currently available, of which rotavirus vaccines have been the most outstanding in demonstrating a significant impact in a short time period. This is a comprehensive review, divided into 2 articles, of nearly 50 vaccine candidates against the most relevant viral and bacterial pathogens that cause acute gastroenteritis. In order to facilitate reading, sections for each pathogen are organized as follows: i) a discussion of the main epidemiological and pathogenic features; and ii) a discussion of vaccines based on their stage of development, moving from current licensed vaccines to vaccines in advanced stage of development (in phase IIb or III trials) to vaccines in early stages of clinical development (in phase I/II) or preclinical development in animal models. In this first article we discuss rotavirus, norovirus and Vibrio cholerae. In the following article we will discuss Shigella, Salmonella (non-typhoidal), diarrheogenic E. coli (enterotoxigenic and enterohemorragic), and Campylobacter jejuni.

show abstract

Section: P Particle-based Vaccines: Researchers From the Cincinnati Cmentioning

confidence: 99%

“…For reviews of specific vaccines we recommend: for rotavirus refs [9][10][11][12][13][15] , for norovirus refs 16,17 ,. for Shigella ref 18 ,.…”

mentioning

confidence: 99%

Vaccines for viral and bacterial pathogens causing acute gastroenteritis: Part I: Overview, vaccines for enteric viruses andVibrio cholerae

O’Ryan

Vidal

Canto

et al. 2015

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

show abstract

“…VLPs have been extensively studied as HuNoV vaccine candidates [73–75] and several formulations have gone through clinical trials [76–80]. There is an excellent review on the recent advances in VLP vaccine development by Tan and Jiang [81]. VLPs are derived by expression of the VP1 capsid protein in eukaryotic expression vectors and produce a capsid similar to the native virion [82].…”

Section: T Cells In Hunov Immunitymentioning

confidence: 99%

“…P particles have become increasingly appealing as vaccine alternatives to VLPs since their development by Tan and Jiang [81,101,112–113]. P particles are made by expression of the VP1 P domain with end-terminal cysteine residues in a prokaryotic expression vector [108].…”

Section: Vectored Vlp Vaccinesmentioning

confidence: 99%

Norovirus Vaccines and Potential Antinorovirus Drugs: Recent Advances and Future Perspectives

Kocher

Yuan

2015

Future Virol.

View full text Add to dashboard Cite

Human noroviruses (HuNoVs) are a leading cause of acute, nonbacterial gastroenteritis worldwide. The lack of a cell culture system and smaller animal model has delayed the development and commercial availability of vaccines and antiviral drugs. Current vaccines rely on recombinant capsid proteins, such as P particles and virus-like particles (VLPs), which have been promising in clinical trials. Anti-HuNoV drug development is another area of extensive research, including currently available antiviral drugs for other viral pathogens. This review will provide an overview of recent advances in vaccine and antiviral development. The implication of recent advances in HuNoV cell culture for improving vaccine and antiviral development is also discussed.

show abstract

“…However, a commercial HEV vaccine remains lacking in other nations. Due to the lack of a cell culture system for NoVs, different subunit NoV vaccines are under development [27], among which VLP-based vaccine has been in phase II clinical trial [28,29]. Recently we have developed a simple technology to turn small antigens into large polymers for improved immunogenicity for vaccine development [30,31].…”

Section: Introductionmentioning

confidence: 99%

A trivalent vaccine candidate against hepatitis E virus, norovirus, and astrovirus

Xia

Wei

Wang

et al. 2016

Vaccine

Self Cite

View full text Add to dashboard Cite

Hepatitis E virus (HEV), norovirus (NoV), and astrovirus (AstV) are enterically-transmitted viral pathogens causing epidemic or endemic hepatitis (HEV) and gastroenteritis (NoV and AstV) respectively in humans, leading to significant morbidity and mortality worldwide. While a recombinant subunit vaccine against HEVs is available in China, there is no commercial vaccine or antiviral against NoV or AstV. We report here our development of a trivalent vaccine against the three viral pathogens through our new polymer vaccine technology. All HEV, NoV, and AstV are non-enveloped RNA viruses covered by a protein capsid, featuring surface protruding (P) proteins that are responsible for virus–host interaction. These dimeric P protein selicit neutralizing antibody and are good targets for subunit vaccine development. The trivalent subunit vaccine was developed by fusion of the dimeric P domains of the three viruses together that formed tetramers. This trivalent vaccine elicited significantly higher antibody responses in mice against all three P domains than those induced by a mixture of the three free P domains (mixed vaccine). Furthermore, the post-immune antisera of the trivalent vaccine showed significantly higher neutralizing titers against HEV infection in cell culture and higher blocking activity on NoV binding to HBGA ligands than those of the post-immune antisera of the mixed vaccine. Thus, the trivalent vaccine is a promising vaccine candidate against HEV, NoV, and AstV.

show abstract

Vaccine against norovirus

Cited by 28 publications

References 95 publications

Vaccines for viral and bacterial pathogens causing acute gastroenteritis: Part I: Overview, vaccines for enteric viruses andVibrio cholerae

Vaccines for viral and bacterial pathogens causing acute gastroenteritis: Part I: Overview, vaccines for enteric viruses andVibrio cholerae

Norovirus Vaccines and Potential Antinorovirus Drugs: Recent Advances and Future Perspectives

A trivalent vaccine candidate against hepatitis E virus, norovirus, and astrovirus

Contact Info

Product

Resources

About